Empowered Patient Podcast

Dr. Alison Darcy is the President and Founder of Woebot Health, an engaging method of delivering self-guided cognitive behavioral therapy on a mobile device. Using only text, Woebot allows the user to interact with a fully automated system with no human intervention but using smart technology that is infinitely patient and never sleeps.

Alison explains, "That also makes it really flexible and flexibly delivered through the health system because it's kind of complimentary to traditional therapy. It can also be and has been used as a very easy on-ramp into the experience of working on one's mental health. It's also been used by people who have already been through therapy and looking for a refresher. It's also been used as a way to just engage with solid mental health-promoting ideas and skills prior to any diagnosable issue."

"What's interesting, actually, from our data, we see that the longest conversations people have with Woebot occur between 2:00 AM and 5:00 AM. I think that's so interesting because these are the moments when there's nobody really around to talk to. And, of course, 80% of all the conversations Woebot has occur outside of traditional clinical hours. So they're happening between 5:00 PM and 8:00 or 9:00 AM the next day. That is a key advantage that a digital solution has."

@HiWoebot #Woebot #DigitalTherapeutics #DigitalHealth #PrescriptionDigitalTherapeutics #MentalHealth #AITechnology

woebothealth.com

Listen to the podcast here

Dr. Alison Darcy is the President and Founder of Woebot Health, an engaging method of delivering self-guided cognitive behavioral therapy on a mobile device. Using only text, Woebot allows the user to interact with a fully automated system with no human intervention but using smart technology that is infinitely patient and never sleeps.

Alison explains, "That also makes it really flexible and flexibly delivered through the health system because it's kind of complimentary to traditional therapy. It can also be and has been used as a very easy on-ramp into the experience of working on one's mental health. It's also been used by people who have already been through therapy and looking for a refresher. It's also been used as a way to just engage with solid mental health-promoting ideas and skills prior to any diagnosable issue."

"What's interesting, actually, from our data, we see that the longest conversations people have with Woebot occur between 2:00 AM and 5:00 AM. I think that's so interesting because these are the moments when there's nobody really around to talk to. And, of course, 80% of all the conversations Woebot has occur outside of traditional clinical hours. So they're happening between 5:00 PM and 8:00 or 9:00 AM the next day. That is a key advantage that a digital solution has."

@HiWoebot #Woebot #DigitalTherapeutics #DigitalHealth #PrescriptionDigitalTherapeutics #MentalHealth #AITechnology

woebothealth.com

Download the transcript here

Paula Brown Stafford is the President, CEO, and Chairman of Novan, which is focused on the research, development, and commercialization of therapies for skin diseases using a novel chemical entity. The first target indication is molluscum contagiosum, a highly contagious viral skin infection caused by molluscipoxvirus with no current FDA-approved treatment.

Paula explains, "The prevalence in the U.S. is around 6 million people, in terms of who gets it. In our clinical trials, which seem to be indicative of the normal population, the average age of the patient is about six and a half, primarily children, one year of age to 14, are the ones who get or are susceptible to this virus."

"Our product candidate is Berdazimer gel 10.3%. It's a topical gel under investigation here at Novan to be a first-in-class therapy for the treatment of molluscum. The active ingredient is Berdazimer sodium, which is a nitric oxide- releasing agent. Our other products potentially for acne, potentially for other areas like psoriasis, et cetera, may have a different percentage number after Berdazimer gel because it refers to the amount of nitric oxide that's in the final product."

@Novan_Biotech #Novan #Dermatology #Molluscum #Pediatrics

novan.com

Listen to the podcast here

Paula Brown Stafford is the President, CEO, and Chairman of Novan, which is focused on the research, development, and commercialization of therapies for skin diseases using a novel chemical entity. The first target indication is molluscum contagiosum, a highly contagious viral skin infection caused by molluscipoxvirus with no current FDA-approved treatment.

Paula explains, "The prevalence in the U.S. is around 6 million people, in terms of who gets it. In our clinical trials, which seem to be indicative of the normal population, the average age of the patient is about six and a half, primarily children, one year of age to 14, are the ones who get or are susceptible to this virus."

"Our product candidate is Berdazimer gel 10.3%. It's a topical gel under investigation here at Novan to be a first-in-class therapy for the treatment of molluscum. The active ingredient is Berdazimer sodium, which is a nitric oxide- releasing agent. Our other products potentially for acne, potentially for other areas like psoriasis, et cetera, may have a different percentage number after Berdazimer gel because it refers to the amount of nitric oxide that's in the final product."

@Novan_Biotech #Novan #Dermatology #Molluscum #Pediatrics

novan.com

Download the transcript here

Jordan Mauriello is the Chief Security Officer at Critical Start and points out the cybersecurity challenges that healthcare organizations, hospitals, individual doctors' offices, and private practices face to protect against cyberattacks. With an eye to how data is stored, Critical Start is looking to reduce opportunities for cybercriminals while, at the same time, planning for a response to a cyberattack.

Jordan explains, "The amount of change that is happening in healthcare actually needs a little bit of a boost. There are changes that have been made, but most healthcare is governed when it comes to cybersecurity by HIPAA. Most of your listeners are familiar with Health Insurance Portability and Accountability Act, which was formed in 1996. And the last time we had a significant change to HIPAA was in 2013. And so when we see the regulatory requirements lagging almost a decade behind what we see here, there's actually quite a bit of change that needs to happen still in healthcare."

"I think the biggest blind spots are still understanding the potential impacts. We've seen hospitals kind of gain notoriety from attacks in the last couple of years. And it's because they have been slower to evolve. Cybercriminals are not slow to evolve. They're always looking for the fastest, most profitable way to monetize a cyberattack. Because they're all about money. It's much different than it was when we saw the hacking movies that came out 20 years ago."

@CriticalStart #HospitalCybersecurity #Cybersecurity #ManagedDetectionandResponse #Cybercriminals #Cyberattack #HIPAA

CriticalStart.com

Listen to the podcast here

Jordan Mauriello is the Chief Security Officer at Critical Start and points out the cybersecurity challenges that healthcare organizations, hospitals, individual doctors' offices, and private practices face to protect against cyberattacks. With an eye to how data is stored, Critical Start is looking to reduce opportunities for cybercriminals while, at the same time, planning for a response to a cyberattack.

Jordan explains, "The amount of change that is happening in healthcare actually needs a little bit of a boost. There are changes that have been made, but most healthcare is governed when it comes to cybersecurity by HIPAA. Most of your listeners are familiar with Health Insurance Portability and Accountability Act, which was formed in 1996. And the last time we had a significant change to HIPAA was in 2013. And so when we see the regulatory requirements lagging almost a decade behind what we see here, there's actually quite a bit of change that needs to happen still in healthcare."

"I think the biggest blind spots are still understanding the potential impacts. We've seen hospitals kind of gain notoriety from attacks in the last couple of years. And it's because they have been slower to evolve. Cybercriminals are not slow to evolve. They're always looking for the fastest, most profitable way to monetize a cyberattack. Because they're all about money. It's much different than it was when we saw the hacking movies that came out 20 years ago."

@CriticalStart #HospitalCybersecurity #Cybersecurity #ManagedDetectionandResponse #Cybercriminals #Cyberattack #HIPAA

CriticalStart.com

Download the transcript here

Yishai Knobel is the Co-Founder and CEO of HelpAround, which is focused on the interoperability of data from providers, payers, vendors, and pharmacies that are part of the specialty patient journey. The HelpAround gateway enables patients to quickly get appropriate drugs with all necessary support to ensure patients can fill specialty prescriptions and stay on their therapy.

Yishai explains, "What we did is basically connect all these silos and create a gateway in the middle that basically gets the right information from all the vendors and makes sure that it is served to the patient in a way that is appropriate and manageable and consumable and actionable. For example, if the patient leaves the office, some of these vendors are not allowed to reach out to the patient until they have a consent signature from the patient that says, "Yes, I'm willing for the pharma company and their proxies to reach out to me." Collecting that consent at the right time is a critical step."

"Just really automating and digitizing a lot of this experience, and meeting the patients where they are, which is literally on their phone, on the go, in a very high-quality personalized experience. Not requiring them to download an app, not requiring them to go through hoops in order to just sign a few forms. Just making it very easy, click, click, click, and check all the boxes you need to check and get on with your life."

#HelpAround #SpecialtyDrugs #SpecialtyPharmaceuticals #SpecialtyPatient #RareDiseases #Oncology #DigitalHealth

HelpAround.co

Listen to the podcast here

Yishai Knobel is the Co-Founder and CEO of HelpAround, which is focused on the interoperability of data from providers, payers, vendors, and pharmacies that are part of the specialty patient journey. The HelpAround gateway enables patients to quickly get appropriate drugs with all necessary support to ensure patients can fill specialty prescriptions and stay on their therapy.

Yishai explains, "What we did is basically connect all these silos and create a gateway in the middle that basically gets the right information from all the vendors and makes sure that it is served to the patient in a way that is appropriate and manageable and consumable and actionable. For example, if the patient leaves the office, some of these vendors are not allowed to reach out to the patient until they have a consent signature from the patient that says, "Yes, I'm willing for the pharma company and their proxies to reach out to me." Collecting that consent at the right time is a critical step."

"Just really automating and digitizing a lot of this experience, and meeting the patients where they are, which is literally on their phone, on the go, in a very high-quality personalized experience. Not requiring them to download an app, not requiring them to go through hoops in order to just sign a few forms. Just making it very easy, click, click, click, and check all the boxes you need to check and get on with your life."

#HelpAround #SpecialtyDrugs #SpecialtyPharmaceuticals #SpecialtyPatient #RareDiseases #Oncology #DigitalHealth

HelpAround.co

Download the transcript here

Joe Hernandez is the Chairman and CEO of Blue Water Vaccines, a spinoff deploying technology from Oxford University. The original focus was on creating a universal flu vaccine that, with one shot, would provide immunity for all the known variations of influenza throughout an individual's lifetime. While continuing vaccine development with partners such as St. Jude's Children's Hospital, Blue Water has expanded its portfolio by identifying transformative vaccines in academic and research labs that can be preventative and prevent long-term diseases.

Joe elaborates, "Where we come in as corporate entities is that we take those technologies and really move them to the next level of development. We find out how we can manufacture them in a way that allows us to create enough material for broad distribution. We design clinical trials, we execute clinical trials, and we deal with the regulatory agencies to get the product approved. Then ultimately, we commercialize with commercial partners. That's kind of the modality that we use here at Blue Water."

"The technology that we in-licensed from the U.K. from Oxford was really derived from a mathematical model that was invented by a scientist there named Sunetra Gupta. Sunetra is by training a mathematician, although she focuses on epidemiological trends in different infectious agents, including malaria and COVID, and a number of other infective agents. But what she discovered, what she stumbled upon as it related to influenza, was that, in fact, influenza was not as diverse as we gave it credit for."

"What we noticed is that the virus, while elusive, really only has a limited ability to hide from the immune system. It has what we call "jackets" or these external codes that the virus uses, but it tends to use it again after a number of iterations. For example, the virus that was present in 1918, the one that was present in 1934, and the current virus have used some of those original "jackets" in the exterior, so we're able to deduce what those are."

@VaccinesInc #BlueWaterVaccines #Flu #Influenza #Vaccines #Vaccinations #FluVaccine #HealthcareInvesting #BigData

BlueWaterVaccines.com

Listen to the podcast here

Joe Hernandez is the Chairman and CEO of Blue Water Vaccines, a spinoff deploying technology from Oxford University. The original focus was on creating a universal flu vaccine that, with one shot, would provide immunity for all the known variations of influenza throughout an individual's lifetime. While continuing vaccine development with partners such as St. Jude's Children's Hospital, Blue Water has expanded its portfolio by identifying transformative vaccines in academic and research labs that can be preventative and prevent long-term diseases.

Joe elaborates, "Where we come in as corporate entities is that we take those technologies and really move them to the next level of development. We find out how we can manufacture them in a way that allows us to create enough material for broad distribution. We design clinical trials, we execute clinical trials, and we deal with the regulatory agencies to get the product approved. Then ultimately, we commercialize with commercial partners. That's kind of the modality that we use here at Blue Water."

"The technology that we in-licensed from the U.K. from Oxford was really derived from a mathematical model that was invented by a scientist there named Sunetra Gupta. Sunetra is by training a mathematician, although she focuses on epidemiological trends in different infectious agents, including malaria and COVID, and a number of other infective agents. But what she discovered, what she stumbled upon as it related to influenza, was that, in fact, influenza was not as diverse as we gave it credit for."

"What we noticed is that the virus, while elusive, really only has a limited ability to hide from the immune system. It has what we call "jackets" or these external codes that the virus uses, but it tends to use it again after a number of iterations. For example, the virus that was present in 1918, the one that was present in 1934, and the current virus have used some of those original "jackets" in the exterior, so we're able to deduce what those are."

@VaccinesInc #BlueWaterVaccines #Flu #Influenza #Vaccines #Vaccinations #FluVaccine #HealthcareInvesting #BigData

BlueWaterVaccines.com

Download the transcript here